Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK01 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- NKGen Biotech, Inc.
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SNK01 + pembrolizumab is a combination therapy consisting of pembrolizumab (a PD-1 inhibitor) and SNK01 (autologous ex-vivo expanded natural killer cells with enhanced cytotoxicity). This combination has shown improved efficacy compared to pembrolizumab monotherapy in advanced non-small cell lung cancer patients who failed prior frontline platinum-based therapy. The therapy works by combining the immune checkpoint inhibition mechanism of pembrolizumab with the enhanced cytotoxicity of SNK01 NK cells, creating a synergistic effect against cancer cells.
- Brand names
- Keytruda
- Other names
- troculeucelautologous NK cell therapySNK01-N12a-Atigen-Cell and Tissue Center-autologous NK cell therapy-cell therapy-Non-small cell lung cancer (NSCLC) — combination with pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SNK01 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK01 + pembrolizumab.